This Week in Biotech – Motley Fool

by admin on May 26, 2013

This Week in Biotech
Motley Fool
XenoPort's management noted that the company plans to cease development of AP and instead focus on the commercial development of recently approved restless leg syndrome drug Horizant, and its remaining clinical pipeline. The ugly. Finally, in a case of

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: